クリニック業績

執筆書籍

・がん疼痛のガイドライン2020年度版　日本緩和医療学会編

システマティックレビュー・デルファイランド　平本秀二、大屋清文

以下よりダウンロードできます。

https://www.jspm.ne.jp/guidelines/pain/2020/pdf/pain2020.pdf

・抗がん剤治療をいつやめるか？どうやめるか？　日本医科大学武蔵小杉病院腫瘍内科教授　勝俣範之編

第１章エビデンスレビュー　やめないとどうなるか？　平本秀二　

・がんと認知機能障害、気づく・評価する・支援する　京都大学　谷向仁編

　　２.がん薬物療法における認知機能障害の特徴　平本秀二

・がん治療医が本当に知りたかった緩和ケアのレシピ　倉田宝保編・蓮尾英明編

　消化管内視鏡ステント留置、胆道ステント留置　平本秀二

・雑誌緩和ケア2021年11月号

　緩和ケアで必須なフィジカルアセスメント身体診察にまつわる実症例 大屋清文

学会発表・講演等

主な国際学会発表

・Hiramoto S, Kato K, Boku N et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in metastatic or recurrent esophageal squamous cell carcinoma. American Society of Clinical Oncology-Gastrointestinal world meeting (ASCO-GI)(米国臨床腫瘍学会消化管世界会議)　2015 in SanFransisco

・Hiramoto S, Tsuneto S, Yoshioka A et al. Status of prognosis prediction in terminal cancer patients at a Japanese general hospital. 14th World Congress of the European Association for Palliative Care (欧州緩和ケア学会) in Copenhagen

・ Hiramoto S, Maeda I, Yoshioka A. et al. Efficacy of palliative radiation for advanced gastric cancer patients.European Society of Medical Oncology (欧州臨床腫瘍学会) congress 2015 in Wien

・Hiramoto S, Maeda I, Morita T et al. Effect of the primary site on the prognosis with advanced-stage cancer in palliative care settings. ASCO (米国臨床腫瘍学会) annual meeting 2016 in Chicago →palliative care とend-of-life careのサブカテゴリーでは日本初

・Hiramoto S, Kikuchi A, Yoshioka A et al. A picture of early death after admission in patients with advanced cancer at the end-of-life.　ASCO palliative oncology care symposium (米国臨床腫瘍学会緩和ケアシンポジウム) 2017 in SanDiego

・Hiramoto S, Yoshioka A, Inoue A et al.　Prognostic impact of end-of-life chemotherapy in the last weeks with advanced cancer.　ESMO (欧州臨床腫瘍学会) congress 2018 in Munch

・Hiramoto S, Hori T, Yoshioka A., et al. Associations between primary cancer site, metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal cancer patients at end-of-life. ESMO (欧州臨床腫瘍学会)GI　2019　in Barcelona

・Hiramoto S, Hori T, Yoshioka A., et al. Association between prognosis and discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received end-of-life chemotherapy. ESMO (欧州臨床腫瘍学会)GI　2019 in Barcelona

・Hiramoto S, Tamaki T, Yoshioka A et al. End-of-life care and prognosis of elderly patients with advanced cancer in palliative care unit. ASCO annual meeting 2020 in Chicago

・Hiramoto S, Yoshioka A, Inoue A et al. Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life. ESMO (欧州臨床腫瘍学会) congress 2020 in Madrid

・Hiramoto S, Kirishima T, Yoshioka A et al. The frequency and predictors of end-of-life symptom in patients with advanced cancer. ASCO annual meeting 2021 in Chicago

・Masuda K, Ishiki H, Hiramoto S et al. Effect of paracentesis on the survival of patients with terminal cancer and ascites: A propensity score-weighted analysis of the EASED study ASCO annual meeting 2021 in Chicago

・Hiramoto S, Tokutani R. Clinical factors associated with survival time from the last administration of systemic anticancer therapy to death in patients with advanced cancer. ESMO (欧州臨床腫瘍学会) congress 2021 in Paris

・(Best Poster Abstract) Oya K et al. Simulation training program for the delivery of death pronouncement, 11th World Research Congress of the EAPC, Palermo, Italy(Online), 2020.

・(Best Poster Award) Oya K et al. Association between bathing and survival in patients with advanced cancer in the terminally ill period: a propensity score analysis, The 13^th Asia Pacific Hospice Conference, Surabaya, Indonesia, 2019.

主な国内学会発表　(シンポジウム)

・平本秀二、菊地綾子、吉岡亮他。オンコロジーと緩和ケアの統合における当院の現状とこれからの課題　第４回サポーティブケア学会シンポジウム　2019

・平本秀二、菊地綾子、吉岡亮他。腫瘍学と在宅ケアの統合におけるサイエンスとアート　第25回日本緩和医療学会シンポジウム　2020

・平本秀二　抗がん剤のやめ時をどう支えるか理論と実践　第26回日本緩和医療学会シンポジウム2021

・平本秀二　腫瘍学と在宅ケアの統合におけるエビデンスとプラクティス　第3回日本在宅医療連合学会シンポジウム　2021

主な講演

平成30年度厚生労働省委託事業　市民公開講座
『あなたを支える緩和ケア～治療も、仕事も、生活も～』

「がん治療と就労問題について考える〜治療医の立場から〜」

平本秀二氏(三菱京都病院腫瘍内科･緩和ケア内科医長)

日本経済新聞掲載

論文・雑誌投稿

国際論文(主著、共著)

・Hiramoto S, Kato K, Boku N, et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. International Journal of Clinical Oncology p1-7, Jan ,20,2018

・Hiramoto S, Yoshioka A, Maeda I et al. Efficacy of palliative radiotherapy and chemo-radiotherapy for unresectable gastric cancer demonstrating bleeding and obstruction. International Journal of Clinical Oncology 2018 Dec;23(6):1090-1094

・Hiramoto S, Yoshioka A, Inoue A, et al. Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer. International Journal of Clinical Oncology 2019 Apr;24(4):454-459.

・Hiramoto S. Yoshioka A, Inoue A, et al. Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life. Palliative & Supportive Care Journal of Clinical Oncology 2020

・Hasuo H, Hiramoto S et al. The usefulness of the armchair sign for the diagnosis of psychosomatic-prone myofascial pain syndrome in patients with incurable cancer: A secondary analysis of a prospective multicenter observational clinical study. Palliat med reports vol2, 2021

・Taniyama T, Hiramoto S, Tokutani R. Risk factors of sudden unexpected death in patients with advanced cancer near the end of life.Palliative & Supportive Care Journal of Clinical Oncology 2021

・Hiratsuka Y, Hiramoto S, Inoue A et al. The Functional Palliative Prognostic Index: a scoring system for functional prognostication of patients with advanced cancer. supportive care in cancer 2020,28(12)

・Amano K, Hiramoto S, Maeda I et al. Effects of enteral nutrition and parenteral nutrition on survival in patients with advanced cancer cachexia: Analysis of a multicenter prospective cohort study.clinical nutrition.2020

・Hamano J, Hiramoto S, Morita T et al. A combination of routine laboratory findings and vital signs can predict survival of advanced cancer patients without physician evaluation: a fractional polynomial model.Dec 2018.European journal of cancer 105:50-60

・Uneno U, Hiramoto S, Morita T et al. Development and validation of a set of six adaptable prognosis prediction (SAP) models based on time-series real-world big data analysis for patients with cancer receiving chemotherapy: A multicenter case crossover study. Aug 2017. PLoS ONE 12(8)

・Mori M, Hiramoto S, Morita T et al. Predictors of response to corticosteroids for dyspnea in advanced cancer patients: a preliminary multicenter prospective observational study. Apr 2017. Supportive care in cancer 25(4)

・Matsuo N, Hiramoto S, Morita T et al. Predictors of Delirium in Corticosteroid-Treated Patients with Advanced Cancer: An Exploratory, Multicenter, Prospective, Observational Study. Feb 2017. Journal of Palliative Medicine 20(4)

・Matsuo N, Hiramoto S, Morita T et al. Predictors of responses to corticosteroids for anorexia in advanced cancer patients: a multicenter prospective observational study. Supportive care in cancer. 2017. 25(1)

・Hamano J, Hiramoto S, Morita T et al. Adding items that assess changes in activities of daily living does not improve the predictive accuracy of the Palliative Prognostic Index. July 2016. Palliative Medicine 31(3)

・Matsuo N, Hiramoto S, Morita T et al. Predictor of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective. Observational Study. May 2016. Journal of Pain and Symptom Management 52(1)

・Baba M, Hiramoto S, Morita T et al. Survival prediction for advanced cancer patients in the real world: A comparison of the Palliative Prognostic Score, Delirium-Palliative Prognostic Score, Palliative Prognostic Index and modified Prognosis in Palliative Care Study predictor model. June 2015.European journal of cancer 23(12)

・Arakawa S, Hiramoto S, Amano K et al. Effects of parenteral nutrition and hydration on survival in advanced cancer patients with malignant bowel obstruction: secondary analysis of a multicenter prospective cohort study. Supportive care in cancer. June 2021.

・Amano K, Hiramoto S, Morita T et al. C-Reactive Protein and Its Relationship with Pain in Patients with Advanced Cancer Cachexia: Secondary Cross-Sectional Analysis of a Multicenter Prospective Cohort Study. Journal of Palliative Medicine. May 2021.

・Ishiki H, Hiramoto S, Nojima M et al. Prevalence of myofascial pain syndrome and efficacy of trigger point injection in patients with incurable cancer. A multicenter, prospective observational study. (MyCar study) Pain Medicine. 23 Dec 2021.

・Oya K, Morita T, Koga H, Mori M, Kashiwagi H, Ohmori T, et al. Association between Bathing and Survival in Patients with Advanced Cancer in Their Last Days of Life: A Prospective Cohort Study. Palliat Med Reports. 2021 Mar 1;2(1):59–64.

・Oya K, Kuboyama Y, Kashiwagi H. Intermittent percutaneous drainage of ovarian tumour. BMJ Support Palliat Care. 2021 May 28;bmjspcare-2020-002873.

・(letter) Oya K, Ishiyama Y, Hideyuki K. Physician Time Spent Using the Electronic Health Record During Outpatient Encounters [Internet]. Vol. 173, Annals of internal medicine. NLM (Medline); 2020. p. 592–3.

・(letter) Ohmori T, Mizuno A, Kawai F, Oya K, Okamura T, Oishi S, et al. Morphine Use for Heart Failure Patients with Renal Insufficiency. Vol. 22, Journal of Palliative Medicine. Mary Ann Liebert Inc.; 2019. p. 617–8.

・Hamano J, Mori M, Ozawa T, Sasaki J, Kawahara M, Nakamura A, Oya K, et al. Comparison of the prevalence and associated factors of hyperactive delirium in advanced cancer patients between inpatient palliative care and palliative home care. Cancer Med. 2021;10(3):1166–79.

・Ito T, Yokomichi N, Ishiki H, Kawaguchi T, Masuda K, Tsukuura H, Oya K, et al. Optimal paracentesis volume for terminally ill cancer patients with ascites. J Pain Symptom Manage [Internet]. 2021;00(00):1–10.

・Imai K, Morita T, Yokomichi N, Kawaguchi T, Kohara H, Yamaguchi T, Oya K, et al. Efficacy of Proportional Sedation and Deep Sedation Defined by Sedation Protocols: A Multicenter, Prospective, Observational Comparative Study. J Pain Symptom Manage. 2021 Jun;00(00):1–10.

・Yutaka Hatano, Tatsuya Morita, Masanori Mori, Isseki Maeda, Shunsuke Oyamada, Akemi Shirado Naito, Kiyofumi Oya, Akihiro Sakashita, Satoko Ito, Yusuke Hiratsuka and Satoru Tsuneto of desire for hastened death in terminally ill cancer patients: A cluster analysis. Palliative Support Care 2021 Mar 1;1-10

国内論文(主著、論文責任著者)

・平本秀二、三宅直樹、河南智春　CDDP／VP-16併用療法が奏効した盲腸内分泌細胞癌の1例　癌と化学療法　2012年8月号

・平本秀二、菊地綾子、吉岡亮　進行胃がん患者に対する緩和的放射線療法の有用性　日本緩和医療学会雑誌　2015 年 10 巻 2 号 p. 514-517

・平本秀二知っておきたいまれな大腸悪性腫瘍【内分泌細胞癌】胃と腸第51巻第3号

・平本秀二　日本消化器病学会雑誌「皮膚悪性黒色腫十二指腸転移の1例」2016年

・堀哲雄、平本秀二、菊地綾子、吉岡亮、玉木朋子単一施設における終末期進行がん患者の入院後早期死亡に関する後方視的研究　日本緩和医療学会雑誌　2017 年 12 巻 4 号 p. 747-752

・菊地綾子、平本秀二、堀哲雄、吉岡亮、長嶋健吾　終末期進行がん患者における長期入院の予測因子と終末期症状・治療との関連　日本緩和医療学会雑誌　2018 年 13 巻 4 号 p. 335-340

・平本秀二「メラノーマと私のキャリアパス」日本医事新報　No4989　2019.12　p3

・平本秀二　國部克彦「Covid-19パンデミック下の医療職における組織コミットメント」　神戸大学経営学研究科 (MBA)　学位論文

治療と緩和ケアの統合

前施設(三菱京都病院)において欧州臨床腫瘍学会(ESMO)より、がん治療と緩和ケアの統合における実践と研究が評価され、責任医師として日本で初めて施設認定受賞(国立がん研究センター東病院、千葉県がんセンターと同時日本初受賞)。平成30年11月 ESMO designated centre of integrated Oncology & Palliative Care 授賞式 (ドイツミュンヘン)(中央は院長、左は緩和ケアの世界的権威Stein Kaasa)